Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evogliptin PK/PD in Renal Impairment
NCT02214693Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Jul 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DA5221-B2 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Dong-A ST. Primary endpoint: Area Under Curve (AUC) last at 120 hours. Started Jul 2014; status: completed.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02214693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02214693.